Clinical Trial

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2022-04-20; most recent amendment 2025-01-29.
Status change: Recruiting → Active, Not Recruiting 2023-12-07
Trial Details
NCT Number NCT05338970
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Enrollment 586 participants
Start Date 2022-07-08
Primary Completion 2024-05-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-31